AI-powered digital pathology for precision prostate cancer management.
Category: Specialized. Pricing: priced per the vendor's website. Last modified: 2026-09-11.
ArteraAI Prostate is an FDA-cleared, AI-powered software-as-a-medical-device (SaMD) that analyzes digital pathology and clinical data to provide risk-stratification insights. It enables clinicians to deliver personalized treatment plans by predicting patient outcomes and therapeutic benefits, such as determining the suitability of short-term androgen deprivation therapy (ST-ADT).
Not editorially tested: One AI Guide has not published a complete hands-on test record for this tool.
Published by LUMIVEX for One AI Guide.
Editorial lead: Said El Moussaoui. Our methodology is published at /how-we-rate.
Official vendor website: see the vendor link below.
ArteraAI Prostate is a specialized tool. AI-powered digital pathology for precision prostate cancer management.
The One AI Guide catalog currently records ArteraAI Prostate as priced per the vendor's website. This is a directory summary, not a current vendor quote; always check the vendor's site for the latest plans before signing up.
The catalog does not currently record ArteraAI Prostate as Free or Freemium. That is not proof that no trial or limited offer exists; check the vendor's site for current options.
Common use cases include Predicting which intermediate-risk prostate cancer patients will benefit from ST-ADT with radiation therapy, Supporting treatment planning for post-prostatectomy BCR patients, and Providing individual risk estimates for metastatic hormone-sensitive prostate cancer (mHSPC).
The One AI Guide catalog currently highlights these strengths: FDA-cleared Software as a Medical Device (SaMD); Non-invasive analysis using existing H&E slides without consuming tissue; Validated performance across diverse populations, including consistent prognostic results for African American men.